Annual report pursuant to Section 13 and 15(d)

1. ORGANIZATION, LIQUIDITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.8.0.1
1. ORGANIZATION, LIQUIDITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
12 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Noncontrolling interests $ (101,246) $ (80,967)
Cash equivalents 0 0
Asset impairment charges $ 0 $ 0
Shares considered antidilutive 7,160,004 3,908,292
Amortization of deferred financing costs $ 0 $ 27,641
Contract revenue 149,625 392,073
Research and development expenses 586,000 673,000
NIH Milestone [Member]    
Contract revenue $ 149,625  
DARPA [Member]    
Contract revenue   387,438
Battelle    
Contract revenue   4,635
ESI [Member]    
Equity ownership percentage 80.00%  
Noncontrolling interest percentage 20.00%  
Noncontrolling interests $ (101,246) $ (80,967)